222 related articles for article (PubMed ID: 23663030)
1. Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA;
J Gastroenterol Hepatol; 2013 Nov; 28(11):1770-81. PubMed ID: 23663030
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
4. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA;
J Viral Hepat; 2011 Aug; 18(8):549-61. PubMed ID: 20626625
[TBL] [Abstract][Full Text] [Related]
5. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
[TBL] [Abstract][Full Text] [Related]
6. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
7. Effects of antiviral therapy on the cellular immune response in acute hepatitis C.
Rahman F; Heller T; Sobao Y; Mizukoshi E; Nascimbeni M; Alter H; Herrine S; Hoofnagle J; Liang TJ; Rehermann B
Hepatology; 2004 Jul; 40(1):87-97. PubMed ID: 15239090
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
Hempel G; Galle PR; Löhr HF
J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
[TBL] [Abstract][Full Text] [Related]
9. Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients.
Yue M; Deng X; Zhai X; Xu K; Kong J; Zhang J; Zhou Z; Yu X; Xu X; Liu Y; Zhu D; Zhang Y
Immunol Lett; 2013 May; 152(2):89-95. PubMed ID: 23680070
[TBL] [Abstract][Full Text] [Related]
10. Viral clearance or persistence after acute hepatitis C infection: interim results from a prospective study.
Guobuzaite A; Chokshi S; Balciūniene L; Voinic A; Stikleryte A; Zagminas K; Ambrozaitis A; Naoumov N
Medicina (Kaunas); 2008; 44(7):510-20. PubMed ID: 18695347
[TBL] [Abstract][Full Text] [Related]
11. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.
Rosen HR; Weston SJ; Im K; Yang H; Burton JR; Erlich H; Klarquist J; Belle SH;
Hepatology; 2007 Aug; 46(2):350-8. PubMed ID: 17659573
[TBL] [Abstract][Full Text] [Related]
12. Insights into the role of HCV Plus-/Minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV.
Alborzi AM; Bamdad T; Davoodian P; Hashempoor T; Nejatizadeh AA; Moayedi J
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):173-81. PubMed ID: 26342113
[TBL] [Abstract][Full Text] [Related]
13. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.
Barnes E; Gelderblom HC; Humphreys I; Semmo N; Reesink HW; Beld MG; van Lier RA; Klenerman P
J Infect Dis; 2009 Mar; 199(6):819-28. PubMed ID: 19434929
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up after successful interferon therapy of acute hepatitis C.
Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
[TBL] [Abstract][Full Text] [Related]
15. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.
Wiegand J; Cornberg M; Aslan N; Schlaphoff V; Sarrazin C; Kubitschke A; Buggisch P; Ciner A; Jaeckel E; Manns MP; Wedemeyer H
Antivir Ther; 2007; 12(3):303-16. PubMed ID: 17591020
[TBL] [Abstract][Full Text] [Related]
16. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
[TBL] [Abstract][Full Text] [Related]
17. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
[TBL] [Abstract][Full Text] [Related]
18. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment.
Shapiro S; Gershtein V; Elias N; Zuckerman E; Salman N; Lahat N
Clin Exp Immunol; 1998 Oct; 114(1):55-60. PubMed ID: 9764603
[TBL] [Abstract][Full Text] [Related]
19. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
20. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
